Loading…
← CockpitCompetitor Analysis › WOCKPHARMA.NS WockhardtOpen in the cockpit ↗

WockhardtWOCKPHARMA.NSCompetitor analysis, valuation and peers

India · INR·Pharma & Healthcare›Pharmaceuticals: Major

Pharmaceutical company developing new antibiotics for drug-resistant infections alongside generic formulation manufacturing.

≈ A small, antibiotic-focused pharma innovatorMomentum leader 81
Mkt cap
$3.52B
US dollars, full cap
Free float
48%
of shares outstanding
$/day
$13.0M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
-11.4 pp
WACC 16.4%
Hurdle
+54 pp
Req g minus delivered
Close · INR₹2,027
1D+0.9%
1W-0.4%
1M+6.3%
3M+9.0%
6M+25.1%
YTD+40.1%
1Y+49.0%
ATR %3.7%
Beta0.90
52w lowhigh16.3% off high

What Wockhardt does

Pharmaceutical company developing new antibiotics for drug-resistant infections alongside generic formulation manufacturing.

Has earned mainly from selling established generic drugs in the UK, Ireland, the US and emerging markets, since it sold its Indian branded-drugs business to Dr. Reddy's in 2020. The antibiotic programme is the research bet on top of that. The Khorakiwala family, who founded the company, remain its controlling shareholders.

In one line: A small, antibiotic-focused pharma innovator.

Products and services

  • Generic formulations
  • Novel antibiotics pipeline
  • Biosimilars/vaccines

Customers

  • Hospitals
  • Pharmacies/distributors globally

Where it sits in the supply chain

  • Novel antibiotic R&D
  • Generic formulation manufacturing
  • Global pharma distribution

What could go right

  • New antibiotic drug approvals
  • Regulated market generic growth

What could go wrong

  • High R&D cost/binary trial risk
  • Legacy debt overhang

Moat: narrow (IP / patents). One of few companies globally developing new antibiotic classes, though commercialization risk remains high.

Headquarters: Mumbai, India · Founded: 1960 · Employees: 4,084

Named competitors

Wockhardt at a glance

Size Wockhardt (WOCKPHARMA.NS) is an India Health Care company (Pharmaceuticals: Major) with a market value of $3.52B, the 262nd largest of 1,066 India companies the cockpit tracks. Shares closed at ₹2,027 on 18 Nov 2026.

Performance Over six months the shares gained 25.1%, against +8.1% for the median peer and +3.8% for the India market (cap-weighted) — 7th highest of 20 in its peer set.

Growth Revenue grew 25.7% over the last twelve months (peer median +9.4%); the operating margin is 13.1% (peer median 12.2%).

Valuation It trades at 9.3× enterprise value to sales against a peer median of 3.2× (3rd most expensive of 16).

Price implies For today's price to make sense, revenue must grow about 58% a year for seven years (Req g). Recent delivered growth is +4%, so the hurdle is +54 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.

Capital Return on invested capital runs 11.4 points below its cost of capital (16.4% WACC).

Relative performance

10012014021 May 202621 Aug 202618 Nov 2026WOCKPHARMA.NS 126Peer median 111
Six months, rebased to 100: Wockhardt against the median of its 20 peers (local-currency closes).

Wockhardt financials

Reported figures in INR; fiscal year ends 2026-03-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue₹37.5B₹33.2B₹29.1B₹27.9B₹26.5B
Revenue growth—+14%+5%+5%—
Gross profit₹14.6B₹9.63B₹6.81B₹5.64B₹4.56B
EBITDA₹7.21B₹5.74B₹3.00B₹1.47B₹790M
Net income₹4.10B₹2.13B-₹470M-₹4.63B-₹5.59B
Free cash flown/a₹640M-₹2.48B-₹340M₹1.11B
Capital expendituren/a₹3.64B₹3.65B₹2.16B₹2.09B
Total debt₹22.4B₹22.3B₹20.2B₹23.6B₹21.8B

Quarterly statements and history in the cockpit →

Wockhardt competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+50%+100%-20%0%+20%+40%SFZNACUTAAS1877ARQT0022623320600521AMLXVRDNPPLPHARMAOGNSLS000739XENE1513ROVIWOCKPHARMA.NS6-month return →1-month return →
Up and to the right = strong over both horizons. Wockhardt is the large dot.

Fundamentals: revenue growth against valuation

-50%0%+50%0×50×100×SFZNACUTAAS1877ARQT002262VRDN2096000739TARSWOCKPHARMA.NSRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Wockhardt is the large dot.

Capital: growth delivered against growth the price implies

0%+100%+200%+300%0%200%ARQT0022623320TARSWOCKPHARMA.NSGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Wockhardt is the large dot.

Wockhardt competitors and peer comparison

Head to head with its named competitors (WOCKPHARMA.NS vs SUNPHARMA.NS vs CIPLA.NS vs AUROPHARMA.NS)
CompanyMarket cap6M returnRevenue growthOp. marginEV / SalesReq g
Wockhardt WOCKPHARMA.NS$3.52B+25%+26%13%9.3×58.0%
Sun Pharmaceutical Industries SUNPHARMA.NS$48.0B-1%+12%23%6.8×28.7%
Cipla CIPLA.NS$12.2B+1%-1%13%3.8×28.4%
Aurobindo Pharma AUROPHARMA.NS$11.0B+19%+14%15%2.8×21.1%
Lupin LUPIN.NS$9.67B-14%+24%24%2.9×8.8%
Dr. Reddy's Laboratories DRREDDY.NS$12.5B+5%-4%9%3.5×30.7%
Basilea Pharmaceutica BSLN.SW$1.04B+33%+5%24%3.2×-5.6%
Shionogi & 4507.T$17.6B+3%+46%29%4.9×0.2%

How Wockhardt compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Wockhardt against its 20 peers (data as of 18 Nov 2026)
MeasureWOCKPHARMA.NSPeer medianRank in peer set
1-month return+6.3%+2.6%8th highest of 21
6-month return+25.1%+8.1%7th highest of 20
Distance from 52-week high-16.3%-23.4%7th highest of 21
Revenue growth (TTM)+25.7%+9.4%7th highest of 18
Operating margin13.1%12.2%8th highest of 16
EV / Sales9.3×3.2×3rd most expensive of 16
Growth the price implies (Req g, 7 yrs)58.0%-0.4%most demanding of 11
Growth delivered (Del g)+4.2%+9.2%3rd lowest of 11
Hurdle (Req g minus delivered)+53.8 pp-11.8 ppmost demanding of 11
ROIC minus cost of capital-11.4 pp+4.3 pp4th lowest of 16
EV / EBITDA48.3×14.5×3rd most expensive of 9
Net debt / EBITDA2.2×1.4×5th least indebted of 9

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Wockhardt WOCKPHARMA.NSIndia$3.52B+25%+26%13%9.3×58.0%+4.2%
Parabilis Medicines PBLSUnited States$3.52Bn/an/an/an/an/an/a
Siegfried SFZN.SWSwitzerland$3.51B-17%+4%16%2.8×n/an/a
Acutaas Chemicals ACUTAAS.NSIndia$3.50B+38%+45%36%20.4×n/an/a
Shanghai Junshi Biosciences 1877.HKHong Kong$3.49B-38%+36%-14%8.4×n/an/a
Arcutis Biotherapeutics ARQTUnited States$3.49B+35%+60%7%6.6×49.2%+367.3%
Jiangsu Nhwa Pharmaceutical 002262.SZChina$3.48B+8%+3%19%3.1×-2.1%+12.0%
China Resources Pharmaceutical 3320.HKHong Kong$3.60B-7%+8%4%0.6×-4.9%+7.8%
Zhejiang Huahai Pharmaceutical 600521.SSChina$3.61B0%+10%12%3.2×6.4%+5.9%
Amylyx Pharmaceuticals AMLXUnited States$3.42B+93%+100%n/an/an/an/a
Viridian Therapeutics VRDNUnited States$3.42B+71%-63%-1,781%106.6×n/an/a
Simcere Pharmaceutical 2096.HKHong Kong$3.42B-5%+27%18%2.6×-3.4%+10.6%
Piramal Pharma PPLPHARMA.NSIndia$3.40B+38%+9%3%3.8×n/an/a
Organon & OGNUnited States$3.66B+3%-3%20%1.8×-4.1%-1.0%
SELLAS Life Sciences SLSUnited States$3.66B+100%n/an/an/an/an/a
Apeloa Pharmaceutical 000739.SZChina$3.37B+17%-16%10%2.5×4.7%+4.5%
Xenon Pharmaceuticals XENEUnited States$3.71B-31%-100%n/an/an/an/a
Viking Therapeutics VKTXUnited States$3.34B-9%n/an/an/an/an/a
Livzon Pharmaceutical 1513.HKHong Kong$3.73B-9%-10%19%2.3×-7.0%+2.0%
Tarsus Pharmaceuticals TARSUnited States$3.74B+17%+86%-10%5.2×34.7%+159.5%
Laboratorios Farmaceuticos Rovi ROVI.MCSpain$3.75B+12%+14%20%4.2×1.2%+12.1%

Questions

Who are Wockhardt's main competitors?
Named competitors: Sun Pharma (SUNPHARMA.NS), Cipla (CIPLA.NS), Entasis Therapeutics (private or unlisted), Aurobindo Pharma (AUROPHARMA.NS), Lupin (LUPIN.NS), Dr. Reddy's Laboratories (DRREDDY.NS). The cockpit's measured peer set (industry) also includes Parabilis Medicines (PBLS), Siegfried (SFZN.SW), Acutaas Chemicals (ACUTAAS.NS), Shanghai Junshi Biosciences (1877.HK), Arcutis Biotherapeutics (ARQT), Jiangsu Nhwa Pharmaceutical (002262.SZ).
Is Wockhardt expensive compared with its peers?
On ev / sales it trades at 9.3× against a peer median of 3.2×, 3rd most expensive of 16 in its peer set. For today's price to make sense, revenue must grow about 58% a year for seven years (Req g). Recent delivered growth is +4%, so the hurdle is +54 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
How has Wockhardt stock performed?
Over six months to 18 Nov 2026 the shares returned +25.1% against +8.1% for the median peer; over one year +49.0%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.